Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The optimal cut-off value in fit-based colorectal cancer screening: An observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Breast cancer survivors' risk of interval cancers and false positive results in organized mammography screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Osteonekrose i relation til lavdosis knoglestyrkende behandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Symptomer fra mundhulen

    Publikation: Bidrag til bog/antologi/rapportBidrag til kompendium/lecture notesUndervisningpeer review

  • Priscila Corraini
  • Uffe Heide-Jørgensen
  • Morten Schiødt
  • Sven Erik Nørholt
  • John Acquavella
  • Henrik Toft Sørensen
  • Vera Ehrenstein
Vis graf over relationer

Osteonecrosis of the jaw (ONJ) is an adverse effect of bone-targeted therapies, which are used to prevent symptomatic skeletal events following bone malignancy. We examined the association between ONJ and survival among cancer patients treated with bone-targeted agents. Using nationwide registries and databases in Denmark, we identified 184 cancer patients with incident ONJ between 2010 and 2015, and a comparison cohort of 1067 cancer patients without ONJ and with a history of hospital-administered treatment with bisphosphonates or denosumab initiating from cancer diagnosis. At the date of confirmed ONJ diagnosis, the comparison cohort was matched to the ONJ patients on age, cancer site, year of cancer diagnosis, and stage at diagnosis. The patients were followed up for survival until emigration or 15 June 2016. We computed overall survival and estimated mortality rate ratios adjusted for sex, and for the presence of distant metastases and other comorbidity at start of follow-up. A match was found for 149 of the 184 ONJ patients. The 1- and 3-year survival among all 184 cancer patients with ONJ was 70% (95% confidence interval [CI]: 63%-76%) and 42% (95% CI: 34%-51%), respectively. Among the matched patients, ONJ was associated with an adjusted mortality rate ratio of 1.31 (95% CI: 1.01-1.71). ONJ was associated with reduced survival among cancer patients treated with bone-targeted agents. ONJ may be a marker of advanced disease or of survival-related lifestyle characteristics.

OriginalsprogEngelsk
TidsskriftCancer Medicine
Vol/bind6
Udgave nummer10
Sider (fra-til)2271-2277
Antal sider7
ISSN2045-7634
DOI
StatusUdgivet - okt. 2017

ID: 56437276